Daiichi Sankyo's Pfaffenhofen site in Germany.
February 20, 2024 07:00 AM EST
Manufacturing

Dai­ichi Sankyo in­vests $1B to bulk out Ger­man site for can­cer AD­Cs 

Anna Brown

News Reporter

Dai­ichi Sankyo is pour­ing €1 bil­lion ($1.07 bil­lion) in­to a Ger­man fa­cil­i­ty in part to ex­pand its ca­pac­i­ty for an­ti­body-drug con­ju­gate …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times